We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

Extraspinal percutaneous osteoplasty for the treatment of painful bony metastasis

Submitted

0 Views
0 Downloads
0 Saves

Presented at

Euroanaesthesia 2017

-

Presentation

thumbnail

Abstract

BACKROUND: Extraspinal percutaneous osteoplasties (POPs) are novel techniques for the treatment of painful bony metastasis, which is oftenthe cause of both persistent and incidental breakthrough pain. This retrospective study explored the efficacy and complications of extraspinal POPs. METHODS: The origin of the cancer metastasis, performed POPsites, necessity of adjacent joint injections, pain and Karnofsky performance scale(KPS)scores, complications related to the POPs, and life expectancy were evaluated from the medical recordsfrom 2009 to 2016. RESULTS: A total of 47(M/F = 28/19) patients had received 55 POPs, including costoplasty, scapuloplasty, ilioplasty, humeroplasty, ischioplasty, femoroplasty, sternoplasty, and puboplasty, in order of frequency. The most common sites forthe origin of the cancer, in order of frequency, were the lung, liver, breast, colon, and kidney. All patients receiving POPsincludingscapuloplasty, ilioplasty,humeroplasty, and femoroplasty needed adjacent joint injections before or after the POPs. Pain due to metastatic lesionswas reduced significantly immediately after the POPsand sustained until the end of their lives. The median KPS was increased from 35.4% to 67.7% immediately after the POPs. There were no complications related to the procedures. The mean life expectancy after performing the POPs, for 35 patients which died afterwards, was 99.3days, ranging from 1 to 767 days. CONCLUSIONS: Even though pain in theisolated POPsites maybe difficult to measure due to overlapping systemic pain, the POPsprovided immediatelocal pain relief, and the patients showed better physical performance without procedure-related complications. (Clinical Trial Number (IRB: 05-2016-159)

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Morressier

Company

Legal

Follow us

© Copyright 2020 Morressier GmbH. All rights reserved.

Morressier

© Copyright 2020 Morressier GmbH.
All rights reserved.